Naszrin Arani, M.D.

hematology/oncology fellow @mdandersonnews▫️ 🇭🇺🇮🇷 ▫️opinions are mine

[Naszrin Arani, M.D. @naszrinMD]

@nihardesai89 @TheUSMLE @PanktiMehta24 Congratulations!

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Delighted to be invited back to speak to our brilliant @UTMDAnderson #LeukemiaFellows for my annual Fellows’ Lecture - Updates on #BPDCN ! Thanks 🙏 @garciamanero @TapKadia Crystal & Erich & team ! @WNMacaron @FiekeHoff @RahulShahK @DanyNassar @naszrinMD #CD123 #BCL2

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Happy @ASH_hematology #ASHAbstractSubmissionDay to all ! #leusm #bmtsm #BPDCN #MPNSM #mmsm #lymsm #ImmunoOnc | @doctorpemm @HannahGoulart @naszrinMD @TapKadia 🙌 | @MPN_Hub @TheIACH @MpncoD @HemeReports @MPN_RF @VJHemOnc @homesforhealers @BloodPortfolio

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Wonderful to come together & spend some time with great friends & trusted colleagues from across the country at @_MDEducation acute leukemia meeting! @LeukDocJZ @beatalleukemia @sanamloghavi @Ramikomrokji @EuniceWangMD @HannahGoulart @TapKadia @ritikulocyte @naszrinMD

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

Hematologist at @ASCO 😂😂

[Daniel Goyco Vera @DanielGoycoMed]

That’s a wrap on #ASCO2026 Great time presenting late infeftious complications of CAR-T for LBCL patients and catching up with old friends from residency @utswcancer

[Naszrin Arani, M.D. @naszrinMD]

@mjmoussa_ @UTMDAnderson @DocMattCampbell @OAlhalabiMD @emanuele_crupi Rockstar!! Congratulations - it was great to meet you!

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉ASCO Poster walk ! Highlighting our amazing early career investigators ! Congratulations to our superstar brilliant heme/Onc fellow MD Dr @naszrinMD on presenting her poster at #ASCO26 | @ASCO #ASCOPosterWalk @Daver_Leukemia @UTMDAnderson #endcancer | 🙏 @TapKadia |

[Naszrin Arani, M.D. @naszrinMD]

@doctorpemm @ASCO @Daver_Leukemia @UTMDAnderson @TapKadia @garciamanero @mtmdphd @HannahGoulart @HimaglobinA @jaltmanmd @TheElfLab Thank you for coming to visit - it was great to see you!!!

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Friday Heme Clinic & Consults teams meet up together at intersection of classical & malignant heme ! @doctorpemm Dr @naszrinMD #DrKroll | @HannahGoulart @HimaglobinA @lungoncdoc @VanMorrisMD @LaurenByersMD

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉 ⁦@US_FDA⁩ approves #ziftomenib for relapsed or refractory acute myeloid leukemia with a #NPM1 mutation | #menin ⁦@GhayasIssa⁩ ⁦@EuniceWangMD⁩ ⁦@madanatyazan⁩ #leusm https://t.co/x8SLLiy1KK

[Nitin Jain @NitinJainMD]

As I start working on a new IST concept, just thought of reposting this thread from 2022

[Walid Macaron, MD MSc @WNMacaron]

Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.

https://t.co/uR43j02ClQ

@NicholasShortMD @DrHKantarjian
#Leusm #ALLsm

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Wonderful to catch up with great colleagues today across @MDAndersonNews ! #endcancer #RareDisease #leusm #MPNSM #BPDCN

[Naveen Pemmaraju, MD @doctorpemm]

Celebrating Dr Arani’s @naszrinMD last day on Leukemia Rotation together ! Great job 👏 and we are looking forward to working with her even more in the future !! #endcancer | @HannahGoulart @HimaglobinA @Apsingh_MD @DanielleHammo20 @jayastuMD 🙏

[Naszrin Arani, M.D. @naszrinMD]

@doctorpemm @HannahGoulart @HimaglobinA @Apsingh_MD @DanielleHammo20 @jayastuMD @Daver_Leukemia This was a great rotation - thank you all!

[Naveen Pemmaraju, MD @doctorpemm]

👉Wonderful Leukemia clinic team ; honored to work with this fantastic dedicated team ! @doctorpemm | Rodney Haltom, PA | Dr Valerie Kalluri | Dr @naszrinMD Dr @wdmarrero Dr Adrianna | @HannahGoulart @HimaglobinA @BKRagonMD @lungoncdoc | #leusm #MPNSM #BPDCN | @homesforhealers

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML. 
 🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️
 🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.
 🔴 NPM1 wildtype relapses occur later and often had MR mutations.  And ALL (8/8) had a different flow immunophenotype compared to original AML.
 🔴We proposed that these were ‘new’ AMLs, that arose from common preleukemic (CH) precursor, but that the original NPM1-mutated AML was ‘cured’.

https://t.co/MTYuZEW15S
@AjHematology

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

American Journal of Hematology | Blood Research Journal | Wiley Online Library #hemepath https://t.co/ZApMZ5YLNA

[Naszrin Arani, M.D. @naszrinMD]

@KellyMezaMD @hsafaMD @BCMDeptMedicine @NarjustFlorezMD @NazliDizman @AnaVManana @ASridharMD @fumikochino @doctorpemm @mpdrc @marthamims @Elkhanany @marklewismd Yay Kelly!!!! Good luck!!!!!